Efficacy of Angiotensin-Receptor Neprilysin Inhibitor Therapy in Patients with Refractory Heart Failure: A Prospective Cohort Study
Pakistan Heart Journal · 28.02.2026 · 59 (1) · 106-111
DOI: 10.47144/phj.v59i1.2941 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Pakistan Heart Journal, online erschienen am 28.02.2026. Verfasst von F A Alaa und 6 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Objectives
Angiotensin receptor-neprilysin inhibitors (ARNI), such as sacubitril/valsartan, induce systemic vasodilation, diuresis, and natriuresis. This study aims to evaluate the effect of ARNI therapy on the quality of life in patients with heart failure (HF). Methodology: A prospective cohort study was conducted on 50 patients diagnosed with ischemic heart disease and heart failure with reduced ejection fraction (HFrEF) (LVEF < 40%). Patients aged 18–80 underwent baseline and follow-up assessments, including clinical examination, echocardiography, laboratory testing, and gated SPECT myocardial perfusion imaging. Following eligibility screening, all 50 participants received ARNI therapy for six months, after which they were reassessed. Key endpoints included changes in New York Heart Association (NYHA) classification, lower limb edema (LLE), and cardiac function parameters such as LVEF, left ventricular end-diastolic volume (LVEDV), and left ventricular end-systolic volume (LVESV).
Results
Significant improvements were observed following six months of ARNI therapy. NYHA class improved, with Class 0 increasing from 0% to 26.09% (P < 0.001). The prevalence of LLE decreased from 100% to 52.17% (P < 0.001). Heart rate significantly decreased (P < 0.001), while systolic and diastolic blood pressure (SBP and DBP) remained unchanged. Gated SPECT imaging revealed a significant increase in LVEF (31.02 ± 8.98% to 36.43 ± 8.39%; P < 0.001) and reductions in LVEDV and LVESV (P < 0.001). Summed rest scores (SRS) for the left anterior descending (LAD) artery, right coronary artery (RCA), and total SRS also showed statistically significant decreases (P < 0.05).
Conclusions
ARNI therapy significantly improved cardiac function, reduced heart failure severity, and enhanced the quality of life in patients with HFrEF. These findings support ARNI as an effective therapeutic option for managing refractory HF.
Zitieren
APA
Alaa, F. A., Mohamed, Y. M., Walid, M. K., Mohamed, F. A., Akram, M. A., Ahmed, I. A., & Alia, H. A. (2026). Efficacy of Angiotensin-Receptor Neprilysin Inhibitor Therapy in Patients with Refractory Heart Failure: A Prospective Cohort Study. Pakistan Heart Journal, 59(1), 106-111. https://doi.org/10.47144/phj.v59i1.2941
Vancouver
Alaa FA, Mohamed YM, Walid MK, Mohamed FA, Akram MA, Ahmed IA, et al. Efficacy of Angiotensin-Receptor Neprilysin Inhibitor Therapy in Patients with Refractory Heart Failure: A Prospective Cohort Study. Pakistan Heart Journal. 2026;59(1):106-111. doi:10.47144/phj.v59i1.2941
BibTeX
@article{Alaa2026,
author = {Alaa, F A and Mohamed, Y M and Walid, M K and Mohamed, F A and Akram, M A and Ahmed, I A and Alia, H A},
title = {Efficacy of Angiotensin-Receptor Neprilysin Inhibitor Therapy in Patients with Refractory Heart Failure: A Prospective Cohort Study},
journal = {Pakistan Heart Journal},
year = {2026},
volume = {59},
number = {1},
pages = {106--111},
doi = {10.47144/phj.v59i1.2941}
}
EUVIMED